Needham Raises Boston Scientific Price Target to $97 After Q4 Beat
Needham raised its price target on Boston Scientific to $97, implying roughly 28.4% upside, after the company reported Q4 revenue of $5.29 billion and adjusted EPS of $0.80, both surpassing consensus. Boston Scientific forecasts 2026 net sales growth of 10.5%–11.5% (10%–11% organic), aiming for $22.18 billion–$22.38 billion in revenue.
1. Fourth-Quarter Earnings Exceed Expectations
Boston Scientific reported Q4 revenues of $5.29 billion, edging past the consensus estimate of $5.28 billion and comfortably within management’s guidance range of $5.22–$5.31 billion. Adjusted EPS came in at $0.80, surpassing the consensus of $0.78 and management guidance of $0.77–$0.79. On a reported basis, sales rose 15.9%, driven by double-digit growth across all major segments, while organic growth reached 12.7%. The cardiovascular segment led the way with 18.2% reported growth, followed by MedSurg at 11.7%.
2. 2026 Guidance Slightly Below Elevated Expectations
For fiscal 2026, Boston Scientific forecasts net sales growth of 10.5–11.5% on a reported basis and 10.0–11.0% organically, which translates to revenues of $22.18–$22.38 billion versus the consensus of $22.37 billion. Adjusted EPS is projected at $3.43–$3.49, marginally below the Street consensus of $3.47. The company expects first-quarter organic revenue growth of 8.5–10.0%, with foreign exchange expected to contribute approximately 200 basis points to reported results.
3. Investor Response and Stock Volatility
Despite the solid beat in Q4 results, the guidance fell one penny short of analyst forecasts, triggering a high-volume sell-off that wiped out months of accumulated gains. The stock plunged by more than 17% on the day following the release, marking its largest one-day decline in over two years. Market observers attributed the sharp reaction to cautious commentary on electrophysiology sales, which underperformed at $890 million versus consensus of $933 million, and a minor safety recall involving AXIOS stents that reported 167 serious injuries and three patient fatalities.
4. Needham’s Bullish Price Target
Needham analyst Mike Matson reiterated a Buy recommendation and set a target of $97, implying upside of approximately 28.4% from recent trading levels. The firm highlighted the company’s resilient free cash flow, projected at $4.2 billion for 2026, and twelve consecutive quarters of double-digit organic growth as underpinning factors for the optimistic outlook. Needham cited robust momentum in Watchman and interventional cardiology products as catalysts that could drive multiple expansion.